Table 1 Demographic data. (A) Displays demographics for the combined LS cohort (rs2075786 and rs2736108 + rs7705526), while (B) Displays demographics for the four countries separately.

From: A genetic variant in telomerase reverse transcriptase (TERT) modifies cancer risk in Lynch syndrome patients harbouring pathogenic MSH2 variants

A

Samples n

Average age* years

Gender Male (%) / female (%)

Gene MLH1 (%) / MSH2 (%) / MSH6 (%)

rs2075786 (n = 1895)

LS cancer

830

45 (16–81)

351 (42)/479 (58)

363 (44) / 342 (41)/124 (15)*

CRC

632

44 (16–79)

316 (50)/316 (50)

315 (50) / 250 (40)/66 (10)

Cancer-free

1065

42 (11–89)

451 (42)/614 (58)

472 (44) / 363 (34)/230 (22)

Total

1895

rs2736108 and rs7705526 (n = 1241)

LS cancer

633

45 (18–84)

266 (42)/367 (58)

292 (46) / 260 (41) / 81 (13)

 

503

44 (18–79)

241 (48)/262 (52)

259 (51) / 199 (40) / 45 (9)

Cancer-free

608

40 (12–81)

246 (40)/362 (60)

303 (50) / 205 (34) / 100 (16)

Total

1241

B

Sample cohort demographics by country

Samples n

Average age* Years (range)

Gender Male (%) / female (%)

Gene MLH1 (%)/MSH2 (%)/MSH6 (%)

LS cancer AU

298

45 (19–81)

173 (58)/125 (42)

106 (36)/136 (46)/56 (18)

LS cancer PL

189

45 (18–71)

121 (64)/68 (36)

101 (54)/74 (39)/14 (7)

LS cancer ES

146

44 (21–79)

73 (50)/72 (50)

85 (58)/50 (34)/11 (8)

LS cancer NL

197

45 (16–78)

112 (57)/85 (43)

71 (36)/82 (42)/43 (22)

Total

803

CRC AU

218

44 (19–75)

113 (52)/105 (48)

92 (42)/99 (45)/27 (13)

CRC PL

150

44 (18–69)

86 (58)/64 (42)

85 (57)/55 (37)/10 (6)

CRC ES

135

44 (21–79)

63 (47)/71 (53)

82 (61)/45 (33)/8 (6)

CRC NL

129

44 (16–72)

54 (42)/75 (58)

56 (43)/51 (40)/21 (17)

Total

632

Cancer-free AU

321

40 (11–81)

196 (61)/124 (39)

129 (40)/112 (35)/80 (25)

Cancer-free PL

193

39 (13–73)

116 (60)/77 (40)

114 (59)/68 (35)/11 (6)

Cancer-free ES

94

41 (12–82)

50 (53)/44 (47)

60 (64)/25 (26)/9 (10)

Cancer-free NL

457

45 (20–89)

252 (55)/205 (45)

169 (37)/158 (35)/130 (28)

Total

1065

  1. * Average age of cancer for cancer patients and average age at last follow up for cancer-free patients.